Transcriptomics

Dataset Information

0

CD4+ T-cell-induced inflammatory killing controls immune evasive tumors


ABSTRACT: Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T-cells to directly recognise and kill tumor cells. These strategies are limited by the emergence of MHC-deficient tumor cells and the development of an immunosuppressive tumor microenvironment. The ability of CD4+ effector cells to contribute to anti-tumor immunity independently of CD8+ T-cells is increasingly recognised, but strategies to unleash their full potential remain to be identified. Here, we describe a mechanism through which a small number of CD4+ T-cells is sufficient to eradicate MHC-deficient tumors that escape direct CD8+ T-cell targeting. The CD4+ effector T-cells preferentially cluster at tumor invasive margins where they interact with MHC-II+CD11c+ antigen-presenting cells. We show that Th1-directed CD4+ T-cells and innate immune stimulation reprogram the tumor-associated myeloid cell network towards IFN-activated antigen-presenting and iNOS-expressing tumoricidal effector phenotypes. Together, CD4+ T-cells and tumoricidal myeloid cells orchestrate a remote inflammatory cell death process that indirectly eradicates IFN-unresponsive and MHC-deficient tumors. These results warrant to clinically exploit the ability of CD4+ T-cells and innate immune stimulators as a strategy to complement the direct cytolytic activity of CD8+ T- and NK-cells and advance cancer immunotherapies.

ORGANISM(S): Mus musculus

PROVIDER: GSE230427 | GEO | 2023/05/24

REPOSITORIES: GEO

Similar Datasets

2023-10-03 | GSE164271 | GEO
2013-01-08 | E-GEOD-41257 | biostudies-arrayexpress
2013-01-08 | GSE41257 | GEO
2022-01-15 | PXD030506 | Pride
2015-02-13 | E-GEOD-64407 | biostudies-arrayexpress
2011-01-27 | E-GEOD-26890 | biostudies-arrayexpress
2015-02-13 | E-GEOD-64408 | biostudies-arrayexpress
2014-02-28 | E-GEOD-49063 | biostudies-arrayexpress
2023-11-13 | GSE235945 | GEO
2011-01-27 | GSE26890 | GEO